Minnesota is currently home to 2102 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)
NCT05586243
Recruiting
Recent studies have has shown that magnetic resonance spectroscopy (MRS) can provide validated neuronal markers in patients with Type 1 GD (GD1) who are on stable therapy. However, alterations in neurometabolites in adult patients with GD3, who have established neurological involvement, are not well understood. The goal of this study is to characterize neurometabolite profiles in adult patients with GD3 using MRS to identify novel biomarkers that can demonstrate treatment response. Additionally,... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/02/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Gaucher Disease, Type 3
Register for Updates
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
NCT06374459
Recruiting
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Register for Updates
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386
Recruiting
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
01/31/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: IC-MPGN
Register for Updates
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
NCT04889430
Recruiting
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/31/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Atypical Hemolytic Uremic Syndrome
Register for Updates
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT04368559
Recruiting
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: University of Minnesota Physicians, Minneapolis, Minnesota
Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Register for Updates
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
NCT01652092
Recruiting
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
Gender:
ALL
Ages:
50 years and below
Trial Updated:
01/31/2025
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Register for Updates
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
NCT01451502
Recruiting
For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. Because of the wide variety of current and potential indications as a source of cells for hematopoietic re... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/31/2025
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Lymphatic Diseases, Hematopoietic Malignancy
Register for Updates
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
NCT06810050
Recruiting
The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 w... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/30/2025
Locations: J&S Studies, Inc., New Brighton, Minnesota
Conditions: Atopic Dermatitis (AD)
Register for Updates
A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction
NCT05891613
Recruiting
The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
01/30/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Breast Reduction
Register for Updates
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
NCT05758246
Recruiting
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes timely treatment with fisetin will interrupt this pathway. A multicenter, randomized, adaptive allocation clinical trial to identify the most... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
01/30/2025
Locations: Ridges, Burnsville, Minnesota
Conditions: Sepsis, Acute Infection, Organ Failure
Register for Updates
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
NCT05238519
Recruiting
The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as clinical and patient-reported outcomes. This study aims to promote optimal disease management and improve outcomes of FH patients.
Gender:
ALL
Ages:
Between 2 years and 75 years
Trial Updated:
01/30/2025
Locations: Aspirus St. Luke's Hospital, Duluth, Minnesota
Conditions: Familial Hypercholesterolemia, Cholesterol, Elevated, Genetic Disease
Register for Updates
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases
NCT05122962
Recruiting
This study is being done to determine the mechanism(s) contributing to the onset of symptoms (i.e. shortness of breath and/or palpitations) as well as changes in heart structure in patients with congenital heart disease (CHD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Tetralogy of Fallot, Congenital Heart Disease
Register for Updates